Popular weight-loss drugs such as Ozempic and Wegovy are transforming obesity treatment, helping many people achieve substantial weight loss. Yet, as the use of these medications expands, researchers are uncovering potential side effects that extend beyond the nausea and digestive problems commonly associated with them. From nail detachment and hair loss to menstrual irregularities, chills and unexplained fatigue, emerging evidence suggests that some symptoms may deserve closer scientific attention.
At the same time, major reviews commissioned by the World Health Organization (WHO) have highlighted important gaps in the evidence supporting these drugs, including limited long-term safety data and the considerable involvement of pharmaceutical manufacturers in clinical research. Together, these findings underscore the need for further independent investigation into the benefits, risks and long-term effects of a rapidly growing class of medications.
Significant Weight Loss, but Important Questions Remain
Last year a Cochrane review commissioned by the WHO examined the effectiveness and safety of glucagon-like peptide-1 (GLP-1) medications used to treat obesity. The analysis included tirzepatide, marketed as Mounjaro and Zepbound; semaglutide, sold as Ozempic and Wegovy; and liraglutide, marketed as Victoza and Saxenda.
The review found that these medications produced substantially greater weight loss than placebos, reinforcing their potential as effective treatments for obesity. However, the researchers also identified important limitations in the available evidence, particularly concerning long-term health outcomes, the frequency and severity of adverse effects, and potential conflicts of interest associated with industry-funded research.
Although the results are encouraging, many clinical trials have been funded by the companies that manufacture the drugs. Researchers say longer-term studies conducted independently of pharmaceutical manufacturers are essential to establish how well the medications work over time, whether their benefits persist and what risks may emerge with prolonged use.
Commonly reported side effects, including nausea, remain an important consideration for patients and clinicians. However, newer research suggests that the range of symptoms associated with GLP-1 use may be broader than previously recognized.
Unexpected Nail Problems Emerge Among GLP-1 Users
One emerging area of concern involves nail health. Research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 identified higher rates of nail detachment and discoloration among people taking GLP-1 medications.
In the first controlled study investigating the potential relationship between these drugs and nail health, researchers examined 575 GLP-1 users and compared them with 1,329 people with type 2 diabetes and/or obesity who had never taken the medications. Participants were recruited from France, the United States, Brazil and Mexico.
The differences between the groups were striking. Nail detachment was reported by 39% of GLP-1 users, compared with just 9% of nonusers. Nail discoloration affected 46% of users, versus 17% of those who had never taken the drugs. Overall, 66% of GLP-1 users reported at least one nail disorder.
The findings raised an important question: Were these problems caused by the medications themselves, or were they a consequence of weight loss?
Rapid weight reduction can affect nutritional intake and other physiological processes that influence the health of nails and hair. However, the researchers found that weight loss alone did not fully explain the differences. Even among participants who had lost weight, GLP-1 users continued to report significantly more nail problems than nonusers.
When the researchers accounted for existing skin conditions and nutritional deficiencies, some differences became smaller. Nevertheless, nail detachment and discoloration remained approximately two to three times more common among GLP-1 users after these adjustments.
While the findings suggest a possible association between the medications and nail changes, they do not establish that the drugs directly cause these problems.
Hair Loss and Scalp Inflammation Raise Further Questions
The potential effects on appearance and skin health were not limited to fingernails. A companion investigation involving the same participants found higher rates of hair loss and scalp symptoms among people taking GLP-1 medications.
Unusual hair loss was reported by 50% of GLP-1 users, compared with 34% of nonusers. Reduced hair volume or density was also more common, affecting 42% of users and 19% of the comparison group.
Hair loss that began after treatment started was reported by 26% of GLP-1 users, compared with 12% of nonusers. Scalp redness was approximately three times more frequent among those taking the medications.
Researchers also observed that hair loss rarely occurred in isolation. Many participants who reported shedding experienced additional scalp symptoms, including itching, redness and flaking.
These accompanying symptoms raise the possibility that inflammation may contribute to the changes in hair health, rather than the symptoms being explained entirely by rapid weight loss. However, further research is needed to determine the underlying mechanisms and whether the medications themselves play a direct role.
The researchers caution that the results should encourage awareness rather than alarm. Both investigations were cross-sectional, meaning they assessed participants' experiences at a particular point rather than tracking changes over time. They also relied on self-reported symptoms rather than standardized clinical examinations.
Consequently, the studies can identify associations and patterns but cannot establish whether GLP-1 medications caused the reported nail, hair or scalp problems.
AI Analysis of Reddit Posts Reveals Other Potential Side Effects
While dermatological research is uncovering possible changes in nail and hair health, another investigation has identified a different set of symptoms discussed by people using GLP-1 medications.
In a study published in Nature Health, researchers used artificial intelligence to analyze more than 400,000 Reddit posts written by nearly 70,000 users over a period of more than five years. Their goal was to identify patterns in patients' experiences that might not be fully captured by clinical trials or conventional drug-safety reporting systems.
The analysis highlighted several symptoms that may warrant closer investigation, including menstrual irregularities, chills, hot flashes and persistent fatigue.
Fatigue was the second most frequently discussed symptom in the Reddit analysis, despite appearing less prominently in many clinical trials. Temperature-related complaints, including feeling unusually cold, chills, hot flashes and fever-like sensations, also emerged as recurring themes.
Reproductive symptoms were another notable finding. Nearly 4% of users reporting side effects described menstrual or other reproductive changes, including irregular cycles, bleeding between periods and unusually heavy bleeding. Researchers suggested that the proportion could be higher in a sample consisting exclusively of women.
These reports do not establish that GLP-1 medications caused the symptoms. However, they identify potential signals that could be investigated through more targeted clinical studies.
Why Social Media Could Help Identify Overlooked Symptoms
Clinical trials are essential for determining whether medications are effective and identifying important safety risks. Nevertheless, they may not capture every symptom patients experience, particularly complaints that are intermittent, difficult to measure or not immediately recognized as potentially related to treatment.
Patients may also discuss symptoms online that they do not mention during medical appointments. By analyzing large volumes of public conversations, AI tools can help researchers identify recurring patterns and generate hypotheses for further investigation.
The researchers emphasized that symptoms such as nausea are already well established. The greater value of the Reddit analysis lies in identifying less-studied complaints that emerge spontaneously in patients' discussions.
However, social media data have significant limitations. People who post about their health online are not necessarily representative of all medication users, and their accounts may lack medical confirmation or important information about other health conditions and treatments. Online reports cannot reliably establish how frequently a symptom occurs across the wider population or whether a particular drug caused it.
AI-assisted analysis should therefore be viewed as a potential early-warning system, not a substitute for controlled clinical research.
Researchers hope to extend their work beyond Reddit and English-speaking communities to determine whether similar patterns appear on other social media platforms and among different populations worldwide.
What the Findings Mean for People Taking GLP-1 Medications
Taken together, the findings illustrate both the promise and the uncertainty surrounding a rapidly expanding class of weight-loss medications.
The WHO-commissioned reviews support the effectiveness of GLP-1 drugs for reducing weight, while highlighting the need for stronger long-term evidence and more independent research. The dermatological investigations raise questions about possible nail, hair and scalp effects, and the AI analysis points to additional symptoms, including menstrual changes, temperature fluctuations and fatigue, that may warrant systematic study.
None of these emerging findings proves that the medications directly cause the reported symptoms. Weight loss itself, nutritional changes, underlying health conditions and other factors could contribute to some of the observed differences. Further research will be needed to separate these possibilities and determine which symptoms, if any, are directly attributable to treatment.
For people taking these medications, the findings are a reason to remain informed rather than assume that unusual symptoms are necessarily drug-related. Anyone experiencing persistent or concerning changes, including significant hair loss, nail detachment or menstrual irregularities, should discuss them with a healthcare professional. Patients should not stop or change prescribed treatment without appropriate medical advice.
The studies also highlight the importance of monitoring patients beyond weight alone. As GLP-1 medications become more widely used, a fuller understanding of their effects on overall health, quality of life and long-term outcomes will be increasingly important.
Ultimately, the challenge is no longer simply to determine whether these drugs can produce substantial weight loss. It is to establish how safely and effectively they can be used over the long term, which patients are most likely to benefit, and how potential adverse effects can be recognized and managed.
Independent clinical trials, longer follow-up periods and innovative approaches to identifying patient-reported symptoms could help answer those questions. For now, GLP-1 medications remain a significant development in obesity treatment, but their impressive results must be considered alongside the continuing need for stronger evidence about their long-term benefits and risks.
Story Sources:
Type 2 Diabetes or Obesity. JAMA Network Open, 2025
Cochrane. "Blockbuster weight loss drugs like Ozempic deliver big results but face big questions." ScienceDaily. February 2026.
Self-reported side effects of semaglutide and tirzepatide in online communities Nature Health, 2026;